Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: BMY/PFE (Eliquis approved in VTE treatment/secondary prevention—entry removed).


ABBV—HCV program: see ENTA.

ENTA/ABBV—3-DAA HCV regimen: PDUFA date on or about 12/21/14; EMA decision on MAA expected 1H15 (MAA submitted 5/8/14). Next-gen 2-DAA regimen (ABT-493 + ABT-530): ph2 combination in HCV patients starts summer 2014; report ph1 data at unspecified venue in 2014.

ENTA/NVS—EDP-239 + Alisporvir: ph2 DDI in healthy volunteers started Jun 2014; ph2b in combination in HCV patients will start after completion of DDI study.

GILD—Sovaldi + Ledipasvir: PDUDA date 10/10/14; EMA decision expected early 2015 (MAA submitted 2/27/14 and “validated” for review 3/27/14).

GILD—TAF (replacement for Viread in HIV combinations): top-line data from treatment-naïve ph3 4Q14; NDA submission 1Q15.

GILD—Standalone elvitegravir PDUFA date 10/3/14; standalone cobicstat PDUFA date 10/4/14. (In the EU, elvitegravir is approved as Vitekta and cobicstat is approved as Tybost.)

MNTA—See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104928571

MRK—Pembrolizumab (MK-3475) in melanoma: PDUFA date 10/2814; EU MAA accepted for review 6/30/14—EU approval possible in 1H15.

NVS—HCV program: see ENTA.

XOMA—EYEGUARD-B ph3 in Behçet’s uveitis: top-line data 2H14.

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).